Pôvodne na liečbu glaukómu, teraz na podporu rastu očných rias.
Latisse contains the same main ingredient as Allergans Lumigan, on the market for glaucoma since 2001. Patients taking Lumigan found a side effect of the drug to be eyelash growth. The drug may also bring in $500 million annually by 2012, and the opportunity could be much larger longer term